Trial Profile
A Double-Blinded, Randomized, Placebo-Controlled, Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANB020 in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Jul 2019
Price :
$35
*
At a glance
- Drugs Etokimab (Primary) ; Etokimab (Primary)
- Indications Asthma; Atopic dermatitis; Peanut hypersensitivity
- Focus Adverse reactions; First in man
- Sponsors AnaptysBio
- 06 Mar 2017 Results presented at the 2017 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
- 24 Feb 2017 Status changed from active, no longer recruiting to completed.
- 13 Feb 2017 According to an AnaptysBio media release, data from this trial will be presented at the 2017 American Academy of Dermatology (AAD) Annual Meeting and the American Academy of Allergy, Asthma and Immunology (AAAAI) 2017 Annual Meeting.